Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The secreted micropeptide C4orf48 enhances renal fibrosis via an RNA-binding mechanism
Jiayi Yang, … , David J. Nikolic-Paterson, Xueqing Yu
Jiayi Yang, … , David J. Nikolic-Paterson, Xueqing Yu
Published April 16, 2024
Citation Information: J Clin Invest. 2024;134(10):e178392. https://doi.org/10.1172/JCI178392.
View: Text | PDF
Research Article Nephrology

The secreted micropeptide C4orf48 enhances renal fibrosis via an RNA-binding mechanism

  • Text
  • PDF
Abstract

Renal interstitial fibrosis is an important mechanism in the progression of chronic kidney disease (CKD) to end-stage kidney disease. However, we lack specific treatments to slow or halt renal fibrosis. Ribosome profiling identified upregulation of a secreted micropeptide, C4orf48 (Cf48), in mouse diabetic nephropathy. Cf48 RNA and protein levels were upregulated in tubular epithelial cells in human and experimental CKD. Serum Cf48 levels were increased in human CKD and correlated with loss of kidney function, increasing CKD stage, and the degree of active interstitial fibrosis. Cf48 overexpression in mice accelerated renal fibrosis, while Cf48 gene deletion or knockdown by antisense oligonucleotides significantly reduced renal fibrosis in CKD models. In vitro, recombinant Cf48 (rCf48) enhanced TGF-β1–induced fibrotic responses in renal fibroblasts and epithelial cells independently of Smad3 phosphorylation. Cellular uptake of Cf48 and its profibrotic response in fibroblasts operated via the transferrin receptor. RNA immunoprecipitation–sequencing identified Cf48 binding to mRNA of genes involved in the fibrotic response, including Serpine1, Acta2, Ccn2, and Col4a1. rCf48 binds to the 3′UTR of Serpine1 and increases mRNA half-life. We identify the secreted Cf48 micropeptide as a potential enhancer of renal fibrosis that operates as an RNA-binding peptide to promote the production of extracellular matrix.

Authors

Jiayi Yang, Hongjie Zhuang, Jinhua Li, Ana B. Nunez-Nescolarde, Ning Luo, Huiting Chen, Andy Li, Xinli Qu, Qing Wang, Jinjin Fan, Xiaoyan Bai, Zhiming Ye, Bing Gu, Yue Meng, Xingyuan Zhang, Di Wu, Youyang Sia, Xiaoyun Jiang, Wei Chen, Alexander N. Combes, David J. Nikolic-Paterson, Xueqing Yu

×

Figure 7

Cf48 enhances the TGF-β1–induced fibrotic response via the transferrin receptor (TFRC).

Options: View larger image (or click on image) Download as PowerPoint
Cf48 enhances the TGF-β1–induced fibrotic response via the transferrin r...
(A) Characterization of recombinant mouse Cf48 (rCf48) lacking the signal peptide (i.e., secreted form) via SDS-PAGE. Stimulation of NRK49F cells (B and C) or NRK52E cells (D) with rCf48 with or without TGF-β1 for 48 hours. Western blots (WBs) show Acta2, collagen I (Col1A1), fibronectin (Fn1), and cadherin-1 expression. (E) Upper panel: NRK49F cells were stimulated for 30 minutes with rCf48 with or without TGF-β1 and expression of total Smad3 (T-Smad3) and C-terminal phosphorylation of Smad3 (p-Smad3) shown by WB. Lower panel: SBE4-luciferase activity assessed in 293T cells 15 hours after stimulation with rCf48 with or without TGF-β1. (F) WB analysis of phosphorylation of p38 MAPK, ERK1/2, and JNK1/2 30 minutes after stimulation of NRK49F cells with rCf48 with or without TGF-β1, TNF-α, or angiotensin II (Ang-II). (G) NRK49F cells were cultured with FLAG-tagged rCf48 for different times (top 2 blots), or with different doses of FLAG-tagged rCf48 for 2 hours (bottom blot). Uptake of FLAG-tagged rCf48 was assessed by WB. (H) Confocal microscopy shows uptake of FLAG-tagged rCf48 (green) 2 hours after addition to NRK49F cells. Scale bars: 5 μm. (I) Confocal microscopy of mouse kidney 5 minutes after tail vein injection of 200 μg of FLAG-tagged rCf48 (green) on day 14 of folic acid–induced neuropathy (FAN). Arrows indicate myofibroblasts double stained for FLAG and Acta2 (yellow). Scale bars: 10 μm. (J) Confocal microscopy showing TFRC expression in renal tubular epithelial cells and myofibroblasts in buffer control mice and on day 14 of FAN. Scale bars: 20 μm. (K) Immunoprecipitation/WB shows an interaction between FLAG-tagged Cf48 and HA-tagged TFRC after both were overexpressed in 293T cells. (L) Surface plasmon resonance (SPR) shows an interaction between rCf48 and recombinant TFRC. (M and N) WB shows that uptake of FLAG-tagged rCf48 after a 2-hour incubation with NRK49F cells can be substantially reduced by pretreatment with a neutralizing anti-TFRC antibody (versus rat IgG control) (M), or by pretreatment with Tfrc siRNA (versus negative control [NC] siRNA) (N). (O) RT-qPCR analysis of Acta2, Ccn2, and Serpine1 mRNA levels 6 hours after FLAG-tagged rCf48 stimulation in NRK49F cells pretreated with control or Tfrc siRNA. Data are expressed as mean ± SD. **P < 0.01; ****P < 0.0001 by 1-way ANOVA with Tukey’s multiple-comparisons test. NS, not significant.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts